Related Experiment Video
Updated: Feb 8, 2026

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
Use of apatinib combined with pemetrexed for advanced ovarian cancer: A case report
Huiting Sun1, Min Xiao, Sufen Liu
1Department of Gynaecology, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University Changzhou Cancer Hospital, Soochow University, Changzhou, China.
Introduction:
Ovarian cancer is the most deadly gynecologic cancer, and the therapy is very difficult. Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2. At present, there are few studies or case reports on apatinib treatment for patients with ovarian cancer.
Case Presentation:
A 75-year-old Chinese woman had a medical history of ovarian high-grade serous papillary adenocarcinoma, who got many lines of chemotherapy and apatinib-an antiangiogenesis drug therapy. Either alone or in combination, apatinib may extend the survival time of patients with advanced ovarian cancer.
Conclusion:
Apatinib may be an option for advanced ovarian cancer after failure of chemotherapy or other targeted therapy. The role of apatinib in the treatment of advanced ovarian cancer needs further study.
Insights
Apatinib, an antiangiogenesis drug, shows potential in treating advanced ovarian cancer, particularly after chemotherapy failure. Further research is needed to confirm its efficacy and role in ovarian cancer therapy.
Area of Science:
- Oncology
- Pharmacology
Background:
- Ovarian cancer is a leading cause of gynecologic cancer deaths, posing significant therapeutic challenges.
- Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2 (VEGFR-2).
Observation:
- A case study involved a 75-year-old woman with advanced ovarian high-grade serous papillary adenocarcinoma.
- The patient received multiple lines of chemotherapy and subsequently apatinib therapy.
Findings:
- Apatinib, as an antiangiogenesis drug, was administered to a patient with refractory ovarian cancer.
- The study suggests apatinib may prolong survival in advanced ovarian cancer patients, alone or in combination.
Implications:
- Apatinib could be a viable treatment option for advanced ovarian cancer post-chemotherapy or other targeted therapies.
- Further clinical studies are essential to establish the definitive role of apatinib in advanced ovarian cancer management.
Related Concept Videos
Data Reporting and Recording
Ovarian Cycle
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:
Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
Extraction: Advanced Methods
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...

